Literature DB >> 20081056

Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients.

Francesca Palandri, Nicola Polverelli, Emanuela Ottaviani, Fausto Castagnetti, Michele Baccarani, Nicola Vianelli.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20081056      PMCID： PMC2878809          DOI： 10.3324/haematol.2009.019190

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  Guido Finazzi; Marco Ruggeri; Francesco Rodeghiero; Tiziano Barbui
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

2.  Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.

Authors:  Guido Finazzi; Alessandro Rambaldi; Vittoria Guerini; Alessandra Carobbo; Tiziano Barbui
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

3.  Clinical manifestations of essential thrombocythemia in young adults.

Authors:  F E Millard; C S Hunter; M Anderson; M J Edelman; M P Kosty; G A Luiken; G G Marino
Journal:  Am J Hematol       Date:  1990-01       Impact factor: 10.047

4.  Long-term use of anagrelide in young patients with essential thrombocythemia.

Authors:  E C Storen; A Tefferi
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

5.  Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.

Authors:  M L Randi; C Rossi; F Fabris; A Girolami
Journal:  Clin Appl Thromb Hemost       Date:  2000-01       Impact factor: 2.389

Review 6.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

Authors:  S Murphy; P Peterson; H Iland; J Laszlo
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

7.  JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.

Authors:  Francesca Palandri; Emanuela Ottaviani; Federica Salmi; Lucia Catani; Nicola Polverelli; Mauro Fiacchini; Giovanni Martinelli; Michele Baccarani; Nicola Vianelli
Journal:  Leuk Lymphoma       Date:  2009-02

8.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

9.  Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry.

Authors:  Lorella Melillo; Alessia Tieghi; Anna Candoni; Franca Radaelli; Rosanna Ciancia; Giorgina Specchia; Bruno Martino; Potito Rosario Scalzulli; Roberto Latagliata; Fausto Palmieri; Emilio Usala; Daniela Valente; Maria Rosa Valvano; Michele Cedrone; Giuseppina Comitini; Vincenzo Martinelli; Nicola Cascavilla; Luigi Gugliotta
Journal:  Am J Hematol       Date:  2009-10       Impact factor: 10.047

10.  Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.

Authors:  A Alvarez-Larrán; F Cervantes; B Bellosillo; M Giralt; A Juliá; J C Hernández-Boluda; A Bosch; L Hernández-Nieto; V Clapés; C Burgaleta; C Salvador; E Arellano-Rodrigo; D Colomer; C Besses
Journal:  Leukemia       Date:  2007-04-12       Impact factor: 11.528
View more
  2 in total

1.  Neurological disorders in essential thrombocythemia.

Authors:  Segolene Billot; Eirini G Kouroupi; Johan Le Guilloux; Bruno Cassinat; Caroline Jardin; Thierry Laperche; Pierre Fenaux; Antoine F Carpentier; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.

Authors:  F Palandri; R Latagliata; N Polverelli; A Tieghi; M Crugnola; B Martino; M Perricone; M Breccia; E Ottaviani; N Testoni; F Merli; F Aversa; G Alimena; M Cavo; G Martinelli; L Catani; M Baccarani; N Vianelli
Journal:  Leukemia       Date:  2015-03-24       Impact factor: 11.528
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.